Provided by Tiger Trade Technology Pte. Ltd.

Precision Biosciences Inc

8.45
-0.4000-4.52%
Pre-market: 8.28-0.1744-2.06%04:28 EDT
Volume:232.78K
Turnover:2.00M
Market Cap:233.23M
PE:-3.02
High:8.82
Open:8.82
Low:8.36
Close:8.85
52wk High:9.62
52wk Low:3.53
Shares:27.60M
Float Shares:25.76M
Volume Ratio:0.67
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8007
EPS(LYR):-3.5649
ROE:-135.15%
ROA:-19.37%
PB:5.15
PE(LYR):-2.37

Loading ...

Precision Biosciences Price Target Maintained with a $60.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 09

Precision Biosciences - Initial Safety Data from Function-dmd Trial Targeted for Year-end 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

Precision Biosciences Posts Updated Corporate Presentation Deck on Investor Website

Reuters
·
Jul 01

Precision BioSciences Joins Russell 2000 Index

MT Newswires Live
·
Jun 30

Precision Biosciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

THOMSON REUTERS
·
Jun 29

Precision BioSciences - Extends Term Loan Maturity Date to December 31, 2029 - SEC Filing

THOMSON REUTERS
·
Jun 17

Precision BioSciences - Enters First Amendment to Loan and Security Agreement With Banc of California - SEC Filing

THOMSON REUTERS
·
Jun 17

Precision BioSciences extends Banc of California term loan maturity to Dec. 31, 2029

Reuters
·
Jun 17

Precision BioSciences Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $20

THOMSON REUTERS
·
Jun 09

H.C. Wainwright Reaffirms Their Buy Rating on Precision BioSciences (DTIL)

TIPRANKS
·
Jun 04

Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)

TIPRANKS
·
May 28

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
May 28

Precision BioSciences presents new data from ELIMINATE-B study at EASL

TIPRANKS
·
May 27

Precision BioSciences reports biopsy evidence of cccDNA elimination in ELIMINATE-B trial of PBGENE-HBV for chronic hepatitis B

Reuters
·
May 27

Precision BioSciences Announces New and Late-Breaking Pbgene-Hbv Clinical Data From the Eliminate-B Study at European Association for the Study of the Liver Congress 2026

THOMSON REUTERS
·
May 27

Precision BioSciences adopts Delaware officer exculpation amendment to charter

Reuters
·
May 27

Precision BioSciences (DTIL) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 22

Precision BioSciences reports new Phase 1 ELIMINATE-B biopsy data for PBGENE-HBV at EASL 2026

Reuters
·
May 21

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Simply Wall St.
·
May 13

Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT)

TIPRANKS
·
May 07